The global diagnostic exosome biomarkers market is anticipated to reach US$ 196.8 million by 2023. Diagnostic exosome biomarkers sales are anticipated to expand at a significant CAGR of 16.3% between 2023 and 2033. By 2033, the diagnostic exosome biomarkers market is expected to be worth US$ 888.5 million.
The market growth can be attributed to the increasing prevalence of cancer, ongoing research on exosomes, and the rising number of clinical studies and trials in exosome-based research expected to spur the diagnostic exosome biomarkers market during the forecast period. Even though there is no FDA-approved clinical exosome product, the number of clinical trials using exosome-based medicines and diagnostics continues to rise.
There has been a rise in studies focusing on comprehending the functionality of exosomes in diseases, especially cancer. Exosomes are associated with several cancer hallmarks that affect tumor spread, immunological regulation, and therapeutic hallmarks.
| Attributes | Diagnostic Exosome Biomarkers Industry (From 2018 to 2022) |
|---|---|
| CAGR | 14.5% |
| Market Size - 2018 | US$ 100.07 million |
| Market Size - 2022 | US$ 172.1 million |
| Attributes | Diagnostic Exosome Biomarkers Industry (From 2023 to 2033) |
|---|---|
| CAGR | 16.3% |
| Market Size - 2023 | US$ 196.8 million |
| Market Size - 2033 | US$ 888.5 million |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
From 2018 to 2022, the diagnostic exosome biomarkers business experienced substantial growth as research and development in exosome-based diagnostics surged.
Advances in technology and an increased understanding of exosomes' role in disease pathology led to identifying potential biomarkers for various conditions, including cancer, neurodegenerative disorders, and infectious diseases. As a result, the diagnostic exosome biomarkers industry witnessed rising investments, product launches, and collaborations between biotech companies and research institutions.
The diagnostic exosome biomarkers market is expected to enter a booming era from 2023 to 2033. With the validation of exosome biomarkers and their adoption in clinical settings, exosome-based tests are likely to become routine diagnostic tools.
The shift toward personalized and non-invasive diagnostics may boost market growth for diagnostic exosome biomarkers, as these tests offer early detection and monitoring capabilities. The expanding applications of exosome-based therapeutics are anticipated to fuel market expansion for diagnostic exosome biomarkers.
Challenges such as standardization, regulatory hurdles, and cost considerations must be addressed to ensure the sustainable growth of the diagnostic exosome biomarkers market in the coming decade.
Growing Investments in the Pharmaceutical Sector to Augment the Market Size
Most biopharmaceutical, pharmaceutical, and medical equipment manufacturers invest hugely in developing novel drugs and devices. Pharmaceutical companies make heavy research and development investments to produce high-quality and innovative products.
The introduction of new technologies is likely to benefit the diagnostic exosome biomarkers industry notably. Exotic devices, a new exosome isolation technology, were introduced recently and expanded significantly over time due to their various benefits, such as purity, high yield, and efficiency. The market is expected to flourish in the forecast period due to such factors.
Principal Consultant
Lack of Awareness and Strict Rules for Product Approval Hamper the Market
Lack of awareness and stringent rules for product approval are expected to hamper the market growth during the forecast period despite various developments in the market. Other factors hampering the market include a lack of unique biomarkers, inefficient separation techniques, and a need for high-resolution visualization equipment limiting understanding of exosomes.
The growing collaboration among diagnostic exosome biomarkers manufacturers is likely to counter the hampering factors and propel growth.
Increasing Demand for Specialized Testing Services to Expand Market Size
The diagnostic exosome biomarkers manufacturers are outsourcing specialized testing services like Liquid Chromatography-Mass Spectrometry, RNA sequencing, wet chemistry, gene expressions, and others earlier in the API process development cycle. These services are mainly used for structural elucidation of key impurities, removing class I and II solvents, removing column chromatography, and efforts toward overall cost reduction and process efficiency.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Category | Product |
|---|---|
| Leading Segment | Reagents & Kits |
| Market Share | 58.8% |
| Category | End User |
|---|---|
| Leading Segment | Diagnostic Centers |
| Market Share | 37.3% |
Reagents and kits lead the demand in the diagnostic exosome biomarkers market. The reagents are essential components used in various diagnostic procedures and research involving exosome biomarkers, making them a fundamental requirement for most applications.
The commercially available kits' convenience and time-saving aspects, including reagents and necessary protocols, attract researchers and clinicians, streamlining the experimental process. Moreover, the increasing adoption of exosome-based diagnostics in various fields, such as oncology and neurology has fueled the demand for efficient and standardized testing solutions, contributing to the popularity of reagents & kits in the market.
Diagnostic centers lead the diagnostic exosome biomarkers sales. The diagnostic centers are dedicated facilities specializing in various diagnostic tests, including advanced biomarker assessments. Their focus on accurate and timely diagnoses attracts many patients seeking cutting-edge diagnostic services.
The diagnostic centers often collaborate with research institutions and pharmaceutical companies, surging demand for exosome biomarker testing in clinical trials and drug development studies. These centers have a broader reach, serving patients from different medical backgrounds, making them a central hub for biomarker-based testing. Also, their expertise, accessibility, and collaborative efforts contribute to their leading position in the diagnostic exosome biomarkers market.
Extensive Research to Develop Key Breakthroughs for Cancer Treatment Fueling Growth Prospects
According to Future Market Insights, the application of exosomes in cancer diagnosis and the development of translational precision medicine is expected to be maximum across cancer institutes. A market share worth 38.4% is anticipated for this segment in 2023.
Exosomes have proven to be highly effective in detecting multiple cancers in their early stages, with a reasonably high degree of sensitivity and specificity. Their intrinsic characteristics provide a unique ability to bypass biological impediments, notably the blood-brain barrier, or BBB. Since exosomes can target particular cell types, the transmission of therapeutic agents by exosomes could be more efficient than other vectors.
| Countries | Value Share in the Global Market |
|---|---|
| North America | 52.6% |
| Europe | 30.6% |
North America is expected to dominate the global diagnostic exosome biomarkers industry during the forecast period. As of 2023, the region is expected to secure about 52.6% of global revenue. Domination of the region can be attributed to established players and the growing launch of products.
Such factors are expected to benefit the regional market in the forecast period.
As per the analysis, Europe is expected to be the second-leading diagnostic exosome biomarkers industry during the forecast period. In 2023, the region is likely to claim 30.6% of revenue. The development of the regional diagnostic exosome biomarkers market can be attributed to the increasing incidences of cancer across the region.
Another factor contributing to the development of the regional market is the government's increasing expenditure on healthcare infrastructure.
| Countries | Market CAGR (From 2023 to 2033) |
|---|---|
| China | 19.8% |
| India | 16.2% |
| Australia | 9.5% |
Asia Pacific is projected to witness maximum growth opportunities, the study reveals. The region's expansion can be attributed to the increasing demand from developing economies like India, China, and Japan. In addition, the rising healthcare expenditures by developing countries are likely to offer remunerative opportunities for market development in the coming time.
Other factors contributing to the market growth for diagnostic exosome biomarkers include the growing prevalence of chronic disorders, increasing healthcare expenditures, and an increasing number of exosome diagnostics. Due to such factors, the diagnostic exosome biomarkers business in the Asia Pacific is likely to expand in the forecast period.
| Countries | Value Share in Global Market |
|---|---|
| The United States | 48.3% |
| Germany | 8.7% |
| Japan | 4.2% |
Codiak Biosciences (USA), Exosome Diagnostics (US), Evox Therapeutics (US), ExoCoBio (South Korea), ILIAS Biologics (South Korea), Anjarium Biosciences (Switzerland), Xollent (US), Craif (Japan), and Carmine Therapeutics (US), are some of the emerging names in the global diagnostic exosome biomarkers market.
Update from the Industry:
Key diagnostic exosome biomarker manufacturers include AMS Biotechnology Limited, 101Bio, BioRegenerative Sciences, Inc., Cell Guidance Systems LLC, Codiak BioSciences, Evomic Science LLC, ExoCyte Therapeutics Pte Ltd, Exovita biosciences, Immune Therapy Holdings AB, Lonza Group, Norgen Biotek Corp., ReNeuron Group plc and Therapeutic Solutions International, Inc.
Novel Developments
| Company | Exo Therapeutics |
|---|---|
| Strategy | Exo Therapeutics Secures US$ 78 million in Series B Financing |
| Details | In October 2021, Exo Therapeutics raised US$ 78 million in series B financing to develop a new strategy for drugging enzymes. Exo has developed an indirect approach to inhibit enzymes by blocking their exosites. |
| Company | Bio-Techne inked |
|---|---|
| Strategy | Bio-Techne and Thermo Fisher Unite for ExoTRU Kidney Transplant Rejection Test |
| Details | In February 2022, Bio-Techne inked an exclusive agreement with Thermo Fisher Scientific for developing and commercializing the ExoTRU kidney transplant rejection test designed by Bio-Techne. This liquid biopsy test provides allograft health information suitable for clinical and research applications. |
The global market size to reach US$ 888.5 million by 2033.
AMS Biotechnology Limited and Lonza Group are the top key players.
The global market is estimated to secure a CAGR 16.3% through 2033.
The rising costs are likely to limit market growth.
The reagents & kits segment is highly preferred in the global market.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Product Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product Type, 2023 to 2033
5.3.1. Reagents
5.3.2. Kits
5.3.3. Serum/Plasma Kits
5.3.4. Urine Kits
5.3.5. Software
5.4. Y-o-Y Growth Trend Analysis By Product Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Product Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Application, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2023 to 2033
6.3.1. Neurodegenerative Disorders
6.3.2. Oncology
6.3.3. Metabolic Disorders
6.3.4. Others
6.4. Y-o-Y Growth Trend Analysis By Application, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Application, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Western Europe
7.3.4. Eastern Europe
7.3.5. South Asia and Pacific
7.3.6. East Asia
7.3.7. Middle East and Africa
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. USA
8.2.1.2. Canada
8.2.2. By Product Type
8.2.3. By Application
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Product Type
8.3.3. By Application
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Product Type
9.2.3. By Application
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Product Type
9.3.3. By Application
9.4. Key Takeaways
10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. UK
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Western Europe
10.2.2. By Product Type
10.2.3. By Application
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Product Type
10.3.3. By Application
10.4. Key Takeaways
11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Poland
11.2.1.2. Russia
11.2.1.3. Czech Republic
11.2.1.4. Romania
11.2.1.5. Rest of Eastern Europe
11.2.2. By Product Type
11.2.3. By Application
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Product Type
11.3.3. By Application
11.4. Key Takeaways
12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Bangladesh
12.2.1.3. Australia
12.2.1.4. New Zealand
12.2.1.5. Rest of South Asia and Pacific
12.2.2. By Product Type
12.2.3. By Application
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Product Type
12.3.3. By Application
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Product Type
13.2.3. By Application
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Product Type
13.3.3. By Application
13.4. Key Takeaways
14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Product Type
14.2.3. By Application
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Product Type
14.3.3. By Application
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. USA
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2022
15.1.2.1. By Product Type
15.1.2.2. By Application
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2022
15.2.2.1. By Product Type
15.2.2.2. By Application
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2022
15.3.2.1. By Product Type
15.3.2.2. By Application
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2022
15.4.2.1. By Product Type
15.4.2.2. By Application
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2022
15.5.2.1. By Product Type
15.5.2.2. By Application
15.6. UK
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2022
15.6.2.1. By Product Type
15.6.2.2. By Application
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2022
15.7.2.1. By Product Type
15.7.2.2. By Application
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2022
15.8.2.1. By Product Type
15.8.2.2. By Application
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2022
15.9.2.1. By Product Type
15.9.2.2. By Application
15.10. Poland
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2022
15.10.2.1. By Product Type
15.10.2.2. By Application
15.11. Russia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2022
15.11.2.1. By Product Type
15.11.2.2. By Application
15.12. Czech Republic
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2022
15.12.2.1. By Product Type
15.12.2.2. By Application
15.13. Romania
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2022
15.13.2.1. By Product Type
15.13.2.2. By Application
15.14. India
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2022
15.14.2.1. By Product Type
15.14.2.2. By Application
15.15. Bangladesh
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2022
15.15.2.1. By Product Type
15.15.2.2. By Application
15.16. Australia
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2022
15.16.2.1. By Product Type
15.16.2.2. By Application
15.17. New Zealand
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2022
15.17.2.1. By Product Type
15.17.2.2. By Application
15.18. China
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2022
15.18.2.1. By Product Type
15.18.2.2. By Application
15.19. Japan
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2022
15.19.2.1. By Product Type
15.19.2.2. By Application
15.20. South Korea
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2022
15.20.2.1. By Product Type
15.20.2.2. By Application
15.21. GCC Countries
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2022
15.21.2.1. By Product Type
15.21.2.2. By Application
15.22. South Africa
15.22.1. Pricing Analysis
15.22.2. Market Share Analysis, 2022
15.22.2.1. By Product Type
15.22.2.2. By Application
15.23. Israel
15.23.1. Pricing Analysis
15.23.2. Market Share Analysis, 2022
15.23.2.1. By Product Type
15.23.2.2. By Application
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Product Type
16.3.3. By Application
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. AMS Biotechnology Limited
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. 101Bio
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. BioRegenerative Sciences
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. Cell Guidance Systems LLC
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. Codiak BioSciences
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. Evomic Science LLC
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. Exovita Biosciences
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. Immune Therapy Holdings AB
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. Lonza Group
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. Norgen Biotek Corp.
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
17.1.11. ReNeuron Group plc
17.1.11.1. Overview
17.1.11.2. Product Portfolio
17.1.11.3. Profitability by Market Segments
17.1.11.4. Sales Footprint
17.1.11.5. Strategy Overview
17.1.11.5.1. Marketing Strategy
17.1.12. Therapeutic Solutions International, Inc.
17.1.12.1. Overview
17.1.12.2. Product Portfolio
17.1.12.3. Profitability by Market Segments
17.1.12.4. Sales Footprint
17.1.12.5. Strategy Overview
17.1.12.5.1. Marketing Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Explore Healthcare Insights
View Reports
Diagnostic Exosome Biomarkers Market
